Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

21. Postoperative incidence of seizure and cerebral infarction in pediatric patients with epileptic type moyamoya disease: a meta-analysis of single rate Full Text available with Trip Pro

Postoperative incidence of seizure and cerebral infarction in pediatric patients with epileptic type moyamoya disease: a meta-analysis of single rate Postoperative incidence of seizure and cerebral infarction in pediatric patients with epileptic type moyamoya disease: a meta-analysis of single rate | Research Square Browse Tools & Services Your Cart This preprint is under consideration at Chinese Neurosurgical Journal . A preprint is a preliminary version of a manuscript that has not completed (...) peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Postoperative incidence of seizure and cerebral infarction in pediatric patients with epileptic type moyamoya disease: a meta-analysis of single rate JINGJING LIU, Qinlan Xu, Hongchuan Niu, Rong Wang

2020 Research Square

22. Symptoms of depression are more frequent in non-surgical patients with left lateralization of Temporal Lobe Epilepsy: A systematic review Full Text available with Trip Pro

studies were evaluated for individual depressive diagnosis, therefore, the analyzed data does not present statistical significance between right and left hemispheres. This study shows mood disorders are prevalent in epileptic patients undergoing clinical treatment. However, to date there is no correlation between lateralization of epilepsy and the prevalence of mood disorders or cognitive impairment. Well-conducted studies are needed to establish the correlation between the epilepsy lateralization (...) of epileptogenic focus is a factor that could contribute to depressive and anxiety symptoms, we propose a systematic review searching for the prevalence of depression in Temporal Lobe Epilepsy in non-surgical patients. We performed a literature search in PubMed/Medline, Web of Science and PsycNET for data from inception until January 2019. The terms “epilepsy, temporal lobe OR “epilepsy” AND “temporal” AND “lobe” OR “temporal lobe epilepsy” OR “temporal” AND “lobe” AND “epilepsy” AND “depressive disorder

2020 Cold Spring Harbor Laboratory

23. Deep brain stimulation for refractory epilepsy in adults

of 52 2 The condition, current treatments and The condition, current treatments and procedure procedure The condition The condition 2.1 Epilepsy is a neurological condition characterised by episodes of abnormal electrical activity in the brain which cause recurrent seizures. The seizures can be focal or generalised. Current treatments Current treatments 2.2 The main treatment for epilepsy is anti-epileptic drugs taken to prevent or reduce the occurrence of seizures. However, many people have drug (...) epilepsy. 1.5 Further research should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction in concomitant medication and hospital admissions. Deep brain stimulation for refractory epilepsy in adults (IPG678) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

24. Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial

of Biomedical and Neuromotor Sciences, University of Bologna, Italy. PMID: 32601123 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To determine whether systematic screening for adverse effects of antiepileptic drugs (AEDs) reduces toxicity burden and improves health-related quality of life in patients with epilepsy. Methods: Consecutive patients with uncontrolled seizures aged ≥16 years and a high Adverse Event Profile (AEP) score were randomized to 2 groups and followed up for 18 months (...) MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM, Striano S, Perucca E; SOPHIE Study Group. Luoni C, et al. Epilepsia. 2011 Dec;52(12):2181-91. doi: 10.1111/j.1528-1167.2011.03325.x. Epilepsia. 2011. PMID: 22136077 Clinical Trial. Micoulaud-Franchi JA, Bartolomei F, Duncan R, McGonigal A. Micoulaud-Franchi JA, et al. Epilepsy Behav. 2017 Oct;75:18-24. doi: 10.1016/j.yebeh.2017.07.016. Epub 2017 Aug 15. Epilepsy Behav. 2017. PMID: 28818810 LeBlanc EL, Patnode CD

2020 EvidenceUpdates

25. Vigabatrin add-on therapy for drug-resistant focal epilepsy. (Abstract)

) and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; low-certainty evidence). Vigabatrin had little to no effect on cognitive outcomes or quality of life.Vigabatrin may significantly reduce seizure frequency in people with drug-resistant focal epilepsy. The results largely apply to adults and should not be extrapolated to children under 10 years old. Short-term follow-up of participants showed that some adverse effects were associated with its use. Analysis of longer-term observational studies elsewhere (...) Vigabatrin add-on therapy for drug-resistant focal epilepsy. This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug licensed for use in drug-resistant epilepsy.To assess the efficacy

2020 Cochrane

26. Perceived Stigma in Epilepsy Patients in a Low Income Country; Ethiopia: A Review and Meta-Analysis of the Prevalence and Related Factors. Full Text available with Trip Pro

(52.2%). Studies published before 2016 provide higher perceived stigma (56.26 %) than studies published after 2016 (35.47%). Our qualitative analysis revealed that rural residence, low level of education and income, age groups of 18 to 24 years, frequent seizure occurrence, contagion believe regarding epilepsy, duration of epilepsy from 1-10 years, depression and anxiety co-morbidity were among the associated factors with perceived stigma in people with epilepsy. Conclusion: The average prevalence (...) Perceived Stigma in Epilepsy Patients in a Low Income Country; Ethiopia: A Review and Meta-Analysis of the Prevalence and Related Factors. Perceived Stigma in Epilepsy Patients in a Low Income Country; Ethiopia: A Review and Meta-Analysis of the Prevalence and Related Factors. | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting

2020 Research Square

27. Zonisamide add-on therapy for focal epilepsy. (Abstract)

Zonisamide add-on therapy for focal epilepsy. The majority of people with epilepsy have a good prognosis, and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop dug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCT) of zonisamide, used as an add-on treatment for focal epilepsy uncontrolled by one or more concomitant antiepileptic drug (...) studies.Randomised controlled trials, in which add-on zonisamide was compared with placebo or another antiepileptic drug in people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drugs.Two review authors independently selected trials for inclusion, extracted data, assessed for risk of bias using the Cochrane 'Risk of bias' tool, and assessed the certainty of the evidence, using the GRADE approach. The primary outcome was at least a 50% reduction in total seizure frequency

2020 Cochrane

28. Effects of Spore Powder of Ganoderma Lucidum on CaSR and apoptosis-related proteins in hippocampus tissue of epilepsy following dementia: a protocol of systematic review Full Text available with Trip Pro

Effects of Spore Powder of Ganoderma Lucidum on CaSR and apoptosis-related proteins in hippocampus tissue of epilepsy following dementia: a protocol of systematic review Inplasy Protocol 505 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

29. Keeping people with epilepsy safe during the COVID-19 pandemic

, impaired immune function due to underlying conditions or drug treatment, and older age, particularly when associated with frailty. People with epilepsy may also have any of these conditions. Because autoimmune disorders are associated with an increased risk of epilepsy and are often treated with immunosuppressive therapies, this is a concern for some people with epilepsy. Individuals with tuberous sclerosis complex, which is often accompanied by epileptic seizures, may have reduced lung function (...) and may also be treated with immune therapy. For certain epilepsy syndromes such as Dravet syndrome, as well as for other epilepsies where seizures are triggered by fever or illness, there may be a risk of worsening in a person with fever due to COVID-19. To date, case reports of worsening have not come forward, which is reassuring. Children are less likely to have severe respiratory illnesses (0.9% 0–14 years in China, 1.5% affected were younger than 20 years in Italy ). c. Are there medications

2020 American Epilepsy Society

30. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures Full Text available with Trip Pro

Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Jun 2;94(22):e2311-e2322. doi: 10.1212/WNL.0000000000009530. Epub 2020 May 14. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures , , , , , , , , , Affiliations Expand Affiliations 1 From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice (...) Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology

2020 EvidenceUpdates

31. Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. (Abstract)

Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. This is an update of the Cochrane Review first published in 2010; it includes one additional study. Primary generalised tonic-clonic seizures are a type of generalised seizure. Other types of seizures include: absence, myoclonic, and atonic seizures. Effective control of tonic-clonic seizures reduces the risk of injury and death, and improves quality of life. While most people achieve seizure control with one (...) antiepileptic drug, around 30% do not, and require a combination of antiepileptic drugs.To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant primary generalised tonic-clonic seizures.For the latest update, we searched these databases on 19 March 2019: Cochrane Register of Studies (CRS) Web, MEDLINE Ovid, and the WHO International Clinical Trials Registry Platform (ICTRP). The CRS includes records from the Cochrane Epilepsy Group Specialized Register, CENTRAL, Embase

2020 Cochrane

32. Ketogenic diets for drug-resistant epilepsy. (Abstract)

Ketogenic diets for drug-resistant epilepsy. Ketogenic diets (KDs) are high in fat and low in carbohydrates and have been suggested to reduce seizure frequency in people with epilepsy. Such diets may be beneficial for children with drug-resistant epilepsy. This is an update of a review first published in 2003, and last updated in 2018.To assess the effects of ketogenic diets for people with drug-resistant epilepsy.For this update, we searched the Cochrane Register of Studies (CRS Web (...) a similar effect on seizure control as the classical KD, but could be associated with fewer adverse effects. This assumption requires more investigation. For people who have drug-resistant epilepsy or who are unsuitable for surgical intervention, KDs remain a valid option. Further research is required, particularly for adults with drug-resistant epilepsy.Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2020 Cochrane

33. Genetic factors and the risk of drug-resistant epilepsy in young children with epilepsy and neurodevelopment disability: A Prospective Study and Updated Meta-Analysis Full Text available with Trip Pro

factors for epilepsy and its seizure outcome in the first 2 years of life are limited. Methods We analyzed data for children aged 0–2 years with epilepsy and neurodevelopmental disability (NDD) from January, 2013, through December, 2017. These patients were followed up to compared the risk of DRE in patients with genetic defect (genetic group) with that without genetic defect (nongenetic group). Additionally, we conducted a meta-analysis to identify the pooled prevalence of genetic factors in children (...) , data regarding the risk factors for epilepsy and its seizure outcome in the first 2 years of life are limited. Methods We analyzed data for children aged 0–2 years with epilepsy and neurodevelopmental disability (NDD) from January, 2013, through December, 2017. These patients were followed up to compared the risk of DRE in patients with genetic defect (genetic group) with that without genetic defect (nongenetic group). Additionally, we conducted a meta-analysis to identify the pooled prevalence

2020 Research Square

34. Postoperative incidence of seizure and ischemic events in patients with epileptic type moyamoya disease: a meta-analysis of single rate Full Text available with Trip Pro

Postoperative incidence of seizure and ischemic events in patients with epileptic type moyamoya disease: a meta-analysis of single rate Postoperative incidence of seizure and ischemic events in patients with epileptic type moyamoya disease: a meta-analysis of single rate | Research Square Browse Tools & Services Your Cart This preprint is under consideration at Chinese Neurosurgical Journal . A preprint is a preliminary version of a manuscript that has not completed peer review at a journal (...) . Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Postoperative incidence of seizure and ischemic events in patients with epileptic type moyamoya disease: a meta-analysis of single rate JINGJING LIU, Qinlan Xu, Hongchuan Niu, Rong Wang, Xun Ye, Xianzeng Liu JINGJING LIU Peking

2020 Research Square

35. Gynecologic Management of Adolescents and Young Women With Seizure Disorders

with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older . General Contraceptive Considerations Adolescents with seizure disorders require ongoing education about potential adverse pregnancy outcomes and the most effective contraceptive options. Ideally, education should begin in early adolescence and continue throughout a patient’s reproductive lifespan because antiepileptic drugs, contraceptive needs, and desire for pregnancy may (...) 2011;52:199–211. Article Locations: Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355–9. Article Locations: Tauboll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015;28:3–11. Article Locations: Morrell MJ, Hayes FJ, Sluss PM, Adams JM, Bhatt M, Ozkara C, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008;64:200–11. Article Locations: Joffe H, Cohen LS

2020 American College of Obstetricians and Gynecologists

36. Readmission rate after epilepsy surgery: A systematic review and meta-analysis Full Text available with Trip Pro

within 30 days was 10% and 9%. The most common cause of re-admission was seizure(31.6%). The overall mean Elixhauser index among readmitted patients after epilepsy surgery was 8.05. Conclusion Minimizing factors that contribute to readmission in various patient populations and procedures becomes important for patient care, resource utilization, and physician reimbursement.understanding about a readmission rate of 10% can be useful to health systems designing quality improvement efforts.Awareness (...) ’, ’reoperation ’ and ‘neurological surgery’. We used random-effects meta-analyses to estimate pooled risk ratios and 95% confidence intervals for early readmission Results In the 7trials reporting readmission rates, the overall prevalence of readmission and re-operation within 30 days was 10% and 9%. The most common cause of re-admission was seizure(31.6%). The overall mean Elixhauser index among readmitted patients after epilepsy surgery was 8.05. Conclusion Minimizing factors that contribute to readmission

2020 Research Square

37. Stiripentol add-on therapy for drug-resistant focal epilepsy. (Abstract)

Stiripentol add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review first published in 2014, and last updated in 2018. For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is an antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam.To evaluate (...) , Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials.Randomised, controlled, add-on trials of stiripentol in people with drug-resistant focal epilepsy.Review authors independently selected trials for inclusion and extracted data. We investigated outcomes including 50% or greater reduction in seizure

2020 Cochrane

38. Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta-analysis Full Text available with Trip Pro

autism spectrum disorder CI confidence interval ES exome sequencing FE focal epilepsy GE generalized epilepsy ID intellectual disability NDDs neurodevelopmental disorders NGS next-generation sequencing panel targeted gene panel sequencing WS west syndrome Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a . Posted May 08, 2020. Thank you for your interest in spreading the word (...) Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta-analysis Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability A systematic review and meta-analysis | medRxiv Search for this keyword Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability A systematic review and meta-analysis Arthur Stefanski , Yamile Calle-López , Costin Leu , Eduardo Pérez

2020 Cold Spring Harbor Laboratory

39. Efficacy and Tolerability of Lamotrigine in the Treatment of Focal Epilepsy in Children and Adolescents: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Efficacy and Tolerability of Lamotrigine in the Treatment of Focal Epilepsy in Children and Adolescents: A Systematic Review and Meta-analysis Inplasy Protocol 246 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 International Platform of Registered Systematic Review and Meta-analysis Protocols

40. Covid-19: Epilepsy

are challenged by the new SARS-CoV-2 virus causing corona virus disease 2019 (COVID-19). The virus is causing mainly viral pneumonia and respiratory tract infection. In this statement, we will focus on the impact of COVID-19 on epilepsy. To our knowledge, no publication covering epilepsy, seizures or paroxysmal events has so far been published in relation to COVID-19. However, there are several general aspects to address: During the previous SARS epidemic, some people with epilepsy (PwE) stopped taking (...) their medicine due to isolation, or fear of contracting infection from hospitals, doctors’ offices, pharmacies or surgical procedures. This obviously leads to an increased risk for seizures and status epilepticus with all related complications including injuries, hospital admissions, and potentially sudden unexpected death in people with epilepsy (SUDEP). Hence, patient information is very important and should stress the importance of maintaining concordance with and supply of prescribed medication. COVID-19

2020 European Academy of Neurology